Secondary outcomes included reductions in waist circumference, blood pressure, and markers of inflammation
An experimental weekly injection demonstrated significant weight reduction in a late-stage clinical trial, with participants losing up to a quarter of their body weight at the highest dosage. The drug, developed as a potential alternative to existing obesity treatments, targets metabolic pathways involved in appetite regulation and energy expenditure. Researchers monitored not only weight changes but also improvements in related health markers among adults with obesity or overweight conditions. The phase 3 study involved over 3,000 participants across multiple countries, all receiving either the investigational drug or a placebo alongside lifestyle interventions. After 72 weeks, those on the highest dose achieved an average weight loss of 25%, surpassing results seen with current leading therapies.
Secondary outcomes included reductions in waist circumference, blood pressure, and markers of inflammation, suggesting broader metabolic benefits beyond weight alone. How Does This Drug Compare to Existing Options? Unlike daily oral medications or less potent weekly injections, this candidate acts on dual receptors to enhance satiety signals and reduce food intake more effectively. Trial data showed consistent dosing led to sustained progress, with fewer participants discontinuing due to side effects compared to some existing regimens. Researchers noted the mechanism may offer advantages for individuals who have not responded adequately to other treatments. What Are the Implications for Long-Term Use? Safety profiles remained favorable throughout the trial, with gastrointestinal symptoms being the most common adverse events, typically mild to moderate and transient. Experts caution that long-term data beyond the study period are still needed to assess durability of effects and any rare risks.
If approved, the drug could expand treatment options for millions struggling with obesity-related health complications. Frequently Asked Questions How much weight did participants lose on average? Participants receiving the highest dose lost an average of 25% of their initial body weight over 72 weeks, significantly more than placebo groups. Was the drug tested alongside diet and exercise? Yes, all participants followed a reduced-calorie diet and increased physical activity regimen throughout the trial to standardize lifestyle factors. What side effects were most commonly reported? Nausea, diarrhea, and vomiting were the most frequent adverse events, generally occurring early in treatment and resolving over time.